Nearly five hundred pet cats across five countries had their tumors genetically sequenced. It is the first large-scale mapping of the feline cancer genome, and the results mirror human cancer genetics to a degree that surprised the researchers.
TP53 — the most frequently mutated gene in human cancer — is also the most frequently mutated gene in cat tumors. FBXW7, a gene whose mutations correlate with poor outcomes in human breast cancer, appeared in over fifty percent of the cat tumors examined. The parallels extend beyond individual genes: the same mutational pathways are activated in feline cancers of the blood, bone, lungs, skin, gastrointestinal tract, and central nervous system.
The reason the overlap matters isn't just comparative genomics. Cats share our environments. They breathe our indoor air, sleep on our furniture, drink our water, and are exposed to the same household chemicals. If the same genes mutate in the same patterns in both species, the shared environment becomes a suspect. Environmental carcinogens that affect cats may also affect the humans living alongside them.
The practical consequence is bidirectional. Human cancer drugs targeting TP53 and FBXW7 pathways may work in cats — veterinary oncology gains new therapeutic candidates without starting from scratch. And feline tumors, which develop faster and in a more compressed timeline than human cancers, become natural models for studying how those mutations drive disease progression.
The cat is not a model organism by design. It became one by cohabitation. The convergence isn't because feline genetics was engineered to resemble ours. It's because living in the same houses, breathing the same air, and accumulating the same exposures drives the same mutations in both species. The shared space produced the shared genome.